CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 77 enrolled
Drug / intervention
Nasal Glucagon +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01994746
NCT01994746Phase 3Completed
CompareCT.gov

Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes

Eli Lilly and Company·interventional·Posted Nov 26, 2013·Updated Sep 23, 2019

In Brief

A Phase 3 clinical trial evaluating Nasal Glucagon and Intramuscular Glucagon for Diabetes Mellitus, Type 1. Completed, enrolled 77 participants across 8 sites.

Detailed Summary

The purpose of this study is to assess the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and safety of 3 milligrams (mg) glucagon (glucagon nasal powder) administered nasally compared with commercially available glucagon given by intramuscular injection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 1
CountriesUnited States
CollaboratorsT1D Exchange Clinic Network Coordinating Center, Locemia Solutions ULC

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 26, 2013
Enrollment StartNov 1, 2013
Primary CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 12.6 years ago

Interventions

Nasal Glucagondrug

Intramuscular Glucagondrug